AeroLeads people directory · profile

Keiji Furuuchi Email & Phone Number

Director, Department of Preclinical Development, Pharmacology lead of CLD Domain, DHBL, Eisai Inc.Discovery Leader of FZEC International Project Team Discovery Leader of BB1701 International Project Team at Eisai US
Location: Narberth, Pennsylvania, United States 11 work roles 1 school
LinkedIn matched
✓ Verified August 2026 3 data sources Profile completeness 86%

Contact Signals

LinkedIn Profile matched
3 free lookups remaining · No credit card
Current company
Role
Director, Department of Preclinical Development, Pharmacology lead of CLD Domain, DHBL, Eisai Inc.Discovery Leader of FZEC International Project Team Discovery Leader of BB1701 International Project Team
Location
Narberth, Pennsylvania, United States
Company size

Who is Keiji Furuuchi? Overview

A concise factual answer block for searchers comparing this professional profile.

Quick answer

Keiji Furuuchi is listed as Director, Department of Preclinical Development, Pharmacology lead of CLD Domain, DHBL, Eisai Inc.Discovery Leader of FZEC International Project Team Discovery Leader of BB1701 International Project Team at Eisai US, a with 2831 employees, based in Narberth, Pennsylvania, United States. AeroLeads shows a matched LinkedIn profile for Keiji Furuuchi.

Keiji Furuuchi previously worked as Discovery Leader of BB1701 IPT at Eisai Us and Director, Pharmacology lead of CLD (Cell lineage and Differentiation) domain, DHBL. at Eisai Us. Keiji Furuuchi holds Phd, Experimental Pathology, Oncology, Tumor Immunology from Hokkaido University.

Company email context

Email format at Eisai US

This section adds company-level context without repeating Keiji Furuuchi's masked contact details.

Eisai US

Review company-level records connected to Keiji Furuuchi before choosing the right outreach path.

Profile bio

About Keiji Furuuchi

* Translational Research* Preclinical research* Biomarker research* Antidoby Drug Conjugates* Bispecific Antibody* Cancer Vaccine* Tumor Immunology* In vivo tumor studySpecialties: Oncology, Immunology, Antibody Engineering

Current workplace

Keiji Furuuchi's current company

Company context helps verify the profile and gives searchers a useful next step.

Eisai US
Eisai Us
Director, Department of Preclinical Development, Pharmacology lead of CLD Domain, DHBL, Eisai Inc.Discovery Leader of FZEC International Project Team Discovery Leader of BB1701 International Project Team
woodcliff lake, new jersey, united states
Website
Employees
2831
AeroLeads page
11 roles

Keiji Furuuchi work experience

A career timeline built from the work history available for this profile.

Discovery Leader Of Bb1701 Ipt

Current

Exton, Pennsylvania, United States

Eisai’s co-development program with BlissBio Pharmaceutical. Eisai formed an IPT (international project team) and I was assigned to be a discovery leader of the program.

Apr 2023 - Present

Director, Pharmacology Lead Of Cld (Cell Lineage And Differentiation) Domain, Dhbl.

Current

Exton, Pennsylvania, United States

Eisai Inc restructured new R&D (Oncology and Neurology as Deep-Human Biology Learning) My responsibility as a pharmacology lead of CLD (Cell lineage and Differentiation) domain is to manage late preclinical stage programs for iND submission and to support clinical development by series of preclinical PoC studies of each project.

Oct 2022 - Present

Discovery Leader Of Fzec (Morab-202) Ipt

Current

Exton, Pennsylvania, United States

I was assigned to serve as a discovery lead for FZEC IPT. My responsibility is to conduct any non-clinical studies to support clinical development of FZEC.

Jun 2020 - Present

Discovery Leader Of Bms And Eisai Joint Translational Research Team For Fzec (Morab-202).

Exton, Pennsylvania, United States

A discovery lead in Eisai/BMS joint TR team of FZEC (MORAb-202) Program.

Jun 2021 - Jun 2024

Director, Prelinical Development, Epat, Obg

United States

I am currently leading the department of Preclinical Development. My team is in charge of late stage programs for achieving IND submission through BLA. The department also takes responsibilities to demonstrate preclinical POC for middle stages of iND-able programs (i.e therapeutic antibodies, Immunotherapy agent, etc).

Jan 2019 - Sep 2022

Director, Preclinical Development

Morphotek, Inc.

United States

Two departments of Pharmacology and Immunotherapy development was merged to form new department, Preclinical development. I was assigned to lead the department. My team took in charge of late stage of programs for achieving IND submission by various preclinical approaches. The department also took responsibilities for middle stages of immunotherapy programs.

Apr 2018 - Dec 2018

Associate Director, Head, Department Of Immunotherapy Development, Preclinical Development

Morphotek, Inc.

United States

The department focus on late stage of programs for the purpose of facilitating IND application. The department also takes responsibilities for middle stages of immunotherapy programs.

Jun 2016 - Mar 2018

Group Leader, Head, Department Of Immunotherapy Development, Preclinical Development

Morphotek, Inc.

United States

The department was placed in newly initiated preclinical development, which focus on late stage of programs for the purpose of facilitating IND application. The department takes responsibilities for those programs and middle stages of immunotherapy agents.

Mar 2016 - May 2016

Group Leader, Head, Immunotherapy Development

Morphotek, Inc.

Exton, Pa

The focus of this department will be to advance next generation antibody leads and antibodies to tumor immune targets.

Sep 2015 - Mar 2016

Group Leader, Antibody Development

Morphotek, Inc.

Exton, Pa

Jun 2014 - Aug 2015

Sr. Scientist, Antibody Development

Morphotek, Inc.

Exton, Pa

Oct 2009 - May 2014
Team & coworkers

Colleagues at Eisai US

Other employees you can reach at eisai.com. View company contacts for 2831 employees →

1 education record

Keiji Furuuchi education

FAQ

Frequently asked questions about Keiji Furuuchi

Quick answers generated from the profile data available on this page.

What company does Keiji Furuuchi work for?

Keiji Furuuchi works for Eisai US.

What is Keiji Furuuchi's role at Eisai US?

Keiji Furuuchi is listed as Director, Department of Preclinical Development, Pharmacology lead of CLD Domain, DHBL, Eisai Inc.Discovery Leader of FZEC International Project Team Discovery Leader of BB1701 International Project Team at Eisai US.

Where is Keiji Furuuchi based?

Keiji Furuuchi is based in Narberth, Pennsylvania, United States while working with Eisai US.

What companies has Keiji Furuuchi worked for?

Keiji Furuuchi has worked for Eisai Us and Morphotek, Inc..

Who are Keiji Furuuchi's colleagues at Eisai US?

Keiji Furuuchi's colleagues at Eisai US include Angelo Wallace, Reyalex Barriga, Yumi Kondo, Ellen Bereznak, and Sue Gray.

How can I contact Keiji Furuuchi?

You can use AeroLeads to view verified contact signals for Keiji Furuuchi at Eisai US, including work email, phone, and LinkedIn data when available.

What schools did Keiji Furuuchi attend?

Keiji Furuuchi holds Phd, Experimental Pathology, Oncology, Tumor Immunology from Hokkaido University.

Find 750M verified contacts

Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.

People with similar names

Check these profiles if this is not the Keiji Furuuchi you were looking for.

View similar profiles